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An increasing proportion of patients with HIV-associated cryptococcal meningitis have received 
antiretroviral therapy (ART) prior to presentation. There is some evidence suggesting an 
increased two-week mortality in those receiving ART for less than 14 days compared with those 
on ART for more than 14 days. However, presentation and outcomes for cryptococcal meningitis 
patients who have recently initiated ART, and those with virologic failure and/or non-
adherence are not well described. 
Methods 
678 adults with first episode of cryptococcal meningitis recruited into a randomized, non-
inferiority, multicentre phase 3 trial in 4 sub-Saharan countries were analysed to compare 
clinical presentation and 2-and 10-week mortality outcomes between ART-naive and 
experienced patients, and between patients receiving ART for varying durations prior to 
presentation.   
Results 
Over half (56% (381/678)) the study participants diagnosed with a first episode of cryptococcal 
meningitis were ART-experienced. All-cause mortality was similar at 2-weeks (17% vs 20%; HR 
0.85, 95%CI 0.6-1.2, p=0.35), and 10 weeks (38% vs 36%; HR 1.03, 95%CI 0.8-1.32, p=0.82) for 
ART-experienced vs ART-naïve patients, respectively. Among ART-experienced patients, using 
different cut-off points for ART duration, there were no significant differences in 2- and 10-
week mortality based on duration of ART.  
Conclusion 
In this study, there were no significant differences in mortality at 2-and 10-weeks between ART- 
naive and experienced patients, and between ART-experienced patients according to duration 
on ART.  
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Cryptococcal meningitis (CM) continues to cause significant morbidity and mortality in  people 
living with HIV (PLHIV) despite the scale-up of antiretroviral therapy (ART) in sub-Saharan 
Africa (SSA) and an increasing proportion of patients with HIV-associated cryptococcal 
meningitis are now presenting on ART (1). Amongst ART experienced patients, a proportion 
will have unmasking immune reconstitution inflammatory response syndrome (usually those 
with ART initiation ~< 3 months prior to presentation), and a proportion will have virological 
and immunological failure due to ART failure (usually those on ART ~> 6 months) (2). Although 
it is well recognised that early initiation of ART during induction treatment of CM results in 
higher mortality (3, 4), data on outcomes for CM patients recently started on ART prior to 
presentation are few, and guidance on ART management (continuation, switch or interruption) 
in this group is based largely on expert opinion (5). Overall mortality appears to be similar 
comparing ART-experienced and ART-naïve cryptococcal meningitis patients (6-9). However, 
differences in presentation and outcomes for patients with ‘unmasking’ cryptococcal infection, 
where ART has been recently initiated, and those with virologic failure and/or non-adherence 
are not well described.  
 
A recent study  of 605 PLHIV diagnosed with CM  in Uganda (10) found no difference in 2-week 
mortality between the ART-experienced and ART-naïve groups but there was increased short-
term mortality in those receiving ART for less than 2 weeks compared with those on ART for 
more than 2 weeks. The study suggested the possibility that pre-existing subclinical meningitis 
in some patients at ART initiation may drive an early unmasking immune reconstitution 
inflammatory response syndrome (IRIS) and increased mortality. Here we have compared 
clinical presentation and short-term mortality outcomes for 678 ART-naïve and ART-
experienced patients with a first episode of CM enrolled into the Advancing Cryptococcal 
meningitis Treatment for Africa (ACTA) trial in 4 countries in SSA (9). The impact of ART 
duration prior to presentation on mortality outcomes were also compared. 
Methods 
Study setting and population 
From January 2013 to November 2016, 721 HIV-infected adults (18 years old) from centres in 
Malawi, Zambia, Tanzania and Cameroon, presenting with a first episode of CM were 
prospectively enrolled into a randomized, noninferiority, multicentre trial (Advancing 

















experienced patients were excluded at the beginning of the trial (4% of enrolment) but an 
amendment allowed inclusion of this population after noting that large number of patients 
exposed to ART were presenting with CM. A total of 678 participants were included in the final 
intention-to-treat analysis.  
 
Study design 
Patients were randomised to 1 of 3 treatment strategies: oral fluconazole plus flucytosine for 2 
weeks, 1-week Amphotericin B (AmB)-based therapy, and standard 2 weeks AmB-based 
therapy (9). Those in the AmB arms were further randomized to flucytosine or fluconazole in a 
1:1 ratio, as the partner drug given with AmB. Patients received consolidation fluconazole 
therapy after the 2-week induction period: 800mg until ART initiation or switch at 4 weeks and 
400mg to 10 weeks. The primary and secondary endpoints were all-cause mortality at 2-weeks 
and 10-weeks respectively.  ART exposure was defined as ever having taken ART. Information 
on ART status and duration on ART was ascertained by self-report (or, where appropriate, from 
guardians) and confirmed by review of medical records. First line ART for adults were tenofovir 
based.  
 
Study outcomes and analysis 
All-cause mortality at 2 and 10 weeks was compared based on ART status (experienced versus 
naïve) and ART duration at CM diagnosis. Baseline clinical and laboratory characteristics were 
compared across ART groups with Chi-square (when sample size is 30 or more) or Fisher exact 
tests (when sample size is less than 30) for categorical variables and Kruskal Wallis tests for 
continuous variables. Unadjusted and adjusted cox proportional hazards models, Kaplan Meier 
curves and log rank tests were used to examine the hazard of mortality between ART-
experienced and ART-naïve patients and for those on ART for varying durations.  Global test 
was conducted to test for non-proportional hazard assumption on the Kaplan Meier curves.  
Adjusted models included known prognostic markers for poor outcome:  age, baseline 
cerebrospinal fluid (CSF) fungal count (quantitative cultures (QCCs) calculated as described 
elsewhere (11)), Glasgow Coma Score (GCS) scale, CSF white blood cell count, haemoglobin, 


















A distinct cut-off for the duration a patient has been taking ART to help distinguish between 
patients experiencing ‘unmasking’ CM and those with virologic failure/non-adherence has not 
been clearly defined. Results from Rhein et al (10) suggested an increased mortality for patients 
receiving ART for ≤14 days compared to those on therapy for 15-182 days or >6 months. 
Therefore, we examined these time periods, and also conducted exploratory analyses to 
understand whether alternative time points with a cut-off of 1 month, 2 months, 3 months and 6 
months could be used to distinguish sub-groups within the ART-experienced population and 
identify any differences in mortality. All analyses were performed in Stata version 15 
((StataCorp LP, College Station, TX)).  
 
Results 
Outcomes by ART status 
A total of 678 patients were included in the study with 56% (381) ART-experienced at baseline 
(Figure 1). Overall, there was little difference in baseline demographics and clinical symptoms 
between ART-naïve and -experienced patients (Table 1), although both median plasma HIV viral 
load and median CSF fungal burden were higher for ART naive patients (p < 0.001). All-cause 
mortality was similar at 2-weeks (17% vs 20%, p=0.39; HR 0.85, 95%CI 0.6-1.2, p=0.35), and 10 
weeks (38% vs 36%, p=0.64; HR 1.03, 95%CI 0.8-1.32, p=0.82) for ART-experienced vs ART-
naïve patients, respectively, with similar results in adjusted analyses (data not shown).  
 
Outcomes by ART duration 
Overall, 66% of patients (251/381) had data on ART duration (Figure 1). At recruitment study 
participants have been on ART for a median (IQR) time of 12 weeks (3 - 91 weeks). 19% 
(47/251) of patients had initiated ART within 14 days prior to presentation, and 61% 
(152/251) within 182 days (Table 1, Supplementary Table 1). There was similarity in the 
distribution of baseline demographics and clinical features between those taking ART for 14 
days compared to those on ART for >14 days, though duration of headache was shorter for 
those taking ART for 14 days (median duration of 7 days vs 14 days; p=0.03) and CSF fungal 
burden was 1 log higher (Table 1). Comparing survival curves there was weak evidence of a 
trend towards increased mortality in those taking ART for 14 days, but there was no 

















3.39, p=0.13), and 10-week mortality was very similar (34% vs 38%; HR 0.92, 95% CI 0.54 to 
1.57, p=0.76) (Fig 2), with similar results in adjusted analyses. 
 
Comparable results were obtained when ART duration was divided into 2 weeks, 15-182 days 
and >182 days, and, with a 1-month cut-off (Supplementary. Table 1, Supplementary Figure 1). 
Higher viral loads and lower CD4 counts were identified for those reportedly on ART for >182 
days compared to those on ART for shorter durations (Supplementary Table 1), consistent with 
the possibility that the former group had a higher proportion of non-adherent patients or 
patients who had developed ART resistance. There were no significant differences in 2- and 10-
week mortality when exploring varying cut-off points for ART duration (Supplementary Table 
2). Using a 1 month cut off, 2-week mortality was 23% for those taking ART for 1 month vs 
14% for those taking ART for >1 month (p=0.08; HR: 1.74, 95%CI: 0.94 to 3.24, p=0.07) but this 
trend did not hold in the adjusted analysis (aHR: 1.44, 95%CI: 0.73 to 2.85, p=0.30).  
 
Discussion 
Over half the patients with a first episode of CM included in this study were ART experienced 
with 14% having started ART in the 14 days prior to diagnosis. Whilst ART-naïve patients had 
higher median HIV plasma viral loads and fungal burdens, there was no evidence for an overall 
difference in mortality between ART-naïve and -experienced populations at both 2 weeks and 
10 weeks. In exploratory analyses according to duration on ART, there was a trend in the 
unadjusted analysis  of increased 2-week mortality for those taking ART for less than 1 month 
compared with those taking ART for >1 month, and the survival curves suggested the possibility 
of an increase in short-term mortality, between 1 and 2 weeks of antifungal treatment, in those 
taking ART for 2 weeks.  Overall, however, we did not identify a cut off for ART duration that 
led to significant differences in short term mortality.  
 
Our findings differ in some respects from the report of Rhein et al. The size of our study is 
similar to that of Rhein and colleagues in Uganda (10) and the findings are in many respects 
similar in terms of the patient populations and differences, for example, in CD4 cell counts and 
cryptococcal colony forming units (CFU) counts between groups. However, we did not find a 
significant difference in short-term mortality in those recently started on ART prior to 

















initiated ART within 2 weeks of presentation. This may simply be because both our studies were 
relatively small with only 51 and 47 patients respectively within the subgroup who had initiated 
ART within 2 weeks of presentation.  
 
In addition, there were some differences in practice. In the study of Rhein, roughly a quarter of 
patients who had initiated ART within 2 weeks of presentation received corticosteroids and / or 
had ART withheld. In the ACTA trial, conducted prior to publication of the Uganda data, ART 
was not routinely  withheld amongst participants who had commenced ART within 6 months of 
presentation with meningitis and who reported and were assessed as adherent to ART. 
Corticosteroids were also not used in this group, in the light of the results of the CryptoDex 
study (12), which found them not to be beneficial, including in the subgroup of patients who had 
initiated ART within 3 months of meningitis diagnosis.   
 
It should be noted that results from this study were limited by missing data for a number of 
patients for duration of taking ART and the fact that the definition for ART exposure was broad. 
Therefore, the study was underpowered to detect differential mortality outcomes among the 
ART-experienced sub-groups. This is because assessing ART adherence retrospectively is very 
difficult. While several measures of checking adherence are operational in most ART programs 
in sub-Saharan Africa drug adherence continues to be an important problem with levels of non-
compliance ranging between 2% and 70% (13). 
 
Data from ongoing randomised studies may help clarify the most appropriate management for 
ART-experienced patients diagnosed with CM.  The ongoing AMBITION-cm trial (14), and 
indeed data from all 3 studies combined (9, 10, 14) presents the opportunity to assess outcomes 
in patients on ART for various durations prior to meningitis. In the AMBITION-cm trial, based on 
a recent consensus among the investigators, including the team from Uganda, the current 
management strategy is to withhold ART for 4-6 weeks in those reportedly adherent and 
started or restarted on ART within the last 14 days, but to continue ART in those reportedly 
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Table 1: Clinical presentation and outcomes by ART status and ART duration.  











Male 173 (58%) 217 (57%) 0.74 30 (64%) 118 (58%) 0.45 
Headache duration 
(days) 
14 (7-21) 14 (7-28) 0.33  7 (7-20) 14 (7-30) 0.03 
Seizures (within 72 
hours) 
54 (18%) 65 (17%) 0.70 9 (19%) 32 (16%) 0.56 
Confusion 119 (40%) 148 (39%) 0.75 22 (47%) 74 (36%) 0.18 
Current TB 36 (12%) 62 (16%) 0.13 8 (17%) 37 (18%) 0.86 
Markers of HIV disease severity 
Anaemia (Hb<7g/dl) 5 (2%) 13 (4%) 0.16 2 (4%) 10 (5%) 0.84 
CD4 count (cells/ml) 25 (10-55) 28 (10-68) 0.51 41 (22-83) 33 (12-78) 0.10 
CD4 count <100 
cells/ml 
250 (91%) 312 (88%) 0.10 33 (81%) 164 (86%) 0.38 
Viral load (log10 
copies/ml) 
5.4 (4.9-5.7) 4.0 (2.5-5.0) <0.001 3.5 (2.9-3.9) 3.8 (2.2-4.9) 0.99 
Markers of severe cryptococcal disease 
Age 50 (years) 34 (12%) 41 (11%) 0.77 7 (15%) 17 (8%) 0.17 
GCS<15 76 (26%) 87 (23%) 0.41 15 (32%) 42 (21%) 0.10 
CSF opening pressure 
>25mmCSF 
125 (46%) 159 (45%) 0.73 21 (50%) 94 (49%) 0.88 
CSF WCC <5 cells/ml 156 (56%) 199 (54%) 0.67 22 (51%) 108 (55%) 0.64 



















5FC-based antifungals 187 (63%) 226 (70%) 0.06 35 (75%) 137 (67%) 0.33 
Number LPs received 3 (2-3) 3 (2-3) 0.9 3 (2-5) 3 (3-4) 0.68 
CSF clearance rate 0.34 (0.23-0.50) 0.33 (0.22-0.50) 0.82 0.36 (0.27-0.63) 0.32 (0.22-0.47) 0.06 
All-cause mortality 
2 weeks 59 (20%) 66 (17%) 0.39 11 (23%) 30 (15%) 0.15 
10 weeks 107 (36%) 144 (38%) 0.64 16 (34%) 78 (38%) 0.59 



















Figure 1: Study Cohort  
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